Navigation Links
VetStem Biopharma Begins Enrollment in Pivotal FDA Clinical Study of Osteoarthritis in Dogs
Date:11/17/2016

VetStem Biopharma, Inc. announced initiation of a pivotal field effectiveness and safety study to evaluate the clinical efficacy and safety of its investigational allogeneic adipose stem cell product. The randomized and blinded placebo-controlled, multi-center study in dogs with clinical osteoarthritis is expected to be completed and submitted to U.S. Food and Drug Administration (FDA) in 2017. The study is being conducted under an FDA-concurred protocol and is supported by VetStem’s US commercial licensee, Aratana Therapeutics.

This pivotal field efficacy study will enroll more than 200 dogs at 17 US veterinary clinics. The stem cell product or placebo will be given as a single injection.

This stem cell product was tested in a large, blinded dose confirmation study and the results were published in the peer-reviewed publication, Frontiers in Veterinary Science and titled “A Prospective, Randomized, Masked, and Placebo-Controlled Efficacy Study of Intraarticular Allogeneic Adipose Stem Cells for the Treatment of Osteoarthritis in Dogs.” Study results showed dogs that received the intraarticular injection of stem cells demonstrated a statistically significant improvement in treatment versus placebo (p<0.05).

Bob Harman, DVM, MPVM, CEO of VetStem stated, “Stem cell therapy for osteoarthritis is a truly novel approach to treatment of a devastating clinical condition of dogs. Donor-derived allogeneic stem cells provide cell therapy in a “ready to use” format without the need for tissue collection, processing or cell culture. VetStem looks forward to the results from this pivotal study, and if favorable, to submitting a major part of the effectiveness data package to the FDA.” If approved, the Company will begin commercialization.

The Company’s stated mission is “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases.” This pivotal study is a key milestone on the path to bring the Company’s first product to market. If approved, this product will be marketed in the US by Aratana Therapeutics, VetStem’s US licensee and commercial partner. VetStem is also in the process of seeking EMA authorization for launch of this product in the European markets and seeks EU and other ex-USA territory commercialization partners.

About VetStem Biopharma
VetStem Biopharma is a veterinarian-lead Company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 14 years and 12,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The Company’s stated mission being “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases.” In addition to its own portfolio of patents, VetStem holds exclusive global veterinary licenses to a portfolio of over 70 issued patents in the field of regenerative medicine.

Read the full story at http://www.prweb.com/releases/2016/11/prweb13839025.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related medicine news :

1. Beckman Coulter Webinar Helps You Skirt the Pitfalls When Automating Cell Viability Counting for Biopharma QC
2. U.S. Ranks 1st in How Its National Policies Impact Global Biopharma Innovation, ITIF Finds in New Analysis Marking World Health Day
3. Reliable Biopharmaceutical Announces New Investor and Chairman
4. Optimizing Early Stage Drug Development and Best Practices in Clinical Trial Supply Management to be Presented by Catalent Experts at Biopharma Asia in Singapore
5. FDAnews Announces — The Biopharmaceutical Facility of the Future: To 2025 and Beyond Webinar, Sept. 29, 2015
6. Dr. Kevin Sadati Discusses the Impact of Allergan Acquiring KYTHERA Biopharmaceuticals
7. Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc.
8. Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting
9. ReveraGen BioPharma Announces Start of Phase 1 Clinical Trial of VBP15 Dissociative Steroid Drug
10. Membrane Technology Market in Pharmaceutical, Biopharma and Life Sciences by Transparency Market Research
11. Keryx Biopharmaceuticals receives FDA approval of ferric citrate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... York, NY (PRWEB) , ... May 26, 2017 , ... ... Health & Wound Care" campaign in USA Today, which will educate readers on how ... side of the campaign, a large focus is placed on melanoma. Dancing with the ...
(Date:5/26/2017)... , ... May 26, 2017 , ... Amir Qureshi, MD ... a powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita SCS System has ... are pleased to be the first in Arkansas to introduce the most powerful SCS ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... the first ever copper, antimicrobial, mesh back 24/7 task chair specifically designed for ... applications. “We are thrilled to partner with Cupron® to provide customers with ...
(Date:5/26/2017)... Illinois (PRWEB) , ... May 26, 2017 , ... Silver ... The community, which is located on more than four acres of land at 5620 ... independence. , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each ...
(Date:5/26/2017)... ... ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: the personal journey of Bob Massey and his ... of published authors, Bob and Margaret Massey. Bob Massey is small in stature but ... leather tough." His love for others is apparent in all of his life decisions. ...
Breaking Medicine News(10 mins):
(Date:5/6/2017)... N.Y. , May 5, 2017  Hill-Rom Holdings, ... will add approximately 100,000 square feet to its Welch ... September 2016 its commitment to bring more than 100 ... , where Welch Allyn has maintained a significant presence ... help accommodate these new positions, a large portion of ...
(Date:5/4/2017)... CAESAREA, Israel , May 4, 2017  DarioHealth ... with mobile health and big data solutions, today announced ... an A&D Company, and STI Technologies Limited to lower ... effective immediately. Through STI,s innoviCares card, which is available ... , DarioHealth customers will be eligible for additional ...
(Date:5/3/2017)... 3, 2017  Getinge, a leading global provider ... enhancement and cost efficiency within healthcare and life ... contemporary practice demonstrating that intra-aortic balloon counterpulsation (IABC) ... ill patients. The single-center, retrospective, observational study showed ... MEGA ® 50cc intra-aortic balloon (IAB) in ...
Breaking Medicine Technology: